<DOC>
	<DOCNO>NCT02493075</DOCNO>
	<brief_summary>The objective study : Phase I : To validate otherwise determine Chinese-specific appropriate contact force PVI PAF.Phase II : To evaluate effectiveness safety ablation guide appropriate contact force .</brief_summary>
	<brief_title>Ablation Paroxysmal Atrial Fibrillation Using Appropriate Contact Force Chinese Population</brief_title>
	<detailed_description>Background： Atrial fibrillation ( AF ) major cause substantial mortality morbidity thromboembolism , heart failure ( HF ) , cognitive dysfunction . With age population improve survival myocardial infarction HF , AF emerge major public health concern . Recently , significant progress make treatment AF catheter ablation , emerge increasingly important technique . According current guideline , catheter ablation consider first-line treatment choice patient drug refractory paroxysmal AF ( PAF ) . Circumferential PV isolation ( CPVI ) widely accept cornerstone procedure , limit unacceptable recurrence rate , mainly due recovery pulmonary vein ( PV ) conduction . Durable , continuous , transmural isolation PV one important goal radiofrequency catheter ablation ( RFCA ) PAF . The contact force ( CF ) ablation catheter target tissue consider closely related ablation effectiveness . Appropriate CF able generate enough tissue lesion , avoid complication , cardiac perforation , atrial-esophageal fistula . Nowadays , irrigated ablation catheter widely use , CF mostly dependent operator ' experience feeling , unable precisely measure . The tissue lesion produce would variable different operator , learn curve would time consume . The newly approve CF catheter enable measurement catheter tip contact force force vector , provide real-time CF ablation . It would helpful , effective lesion formation , also prevention complication . Studies Western-population indicate high long-term successful rate could achieve use CF catheter , CF 10 20g adopted center . It would important find appropriate range CF Chinese population , various factor include instance thinner small atrial chamber among Chinese . Objectives Phase I : To validate otherwise determine Chinese-specific appropriate CF PVI PAF . Phase II : To evaluate effectiveness safety ablation guide appropriate CF Trial design Treatment Subjects Phase I Instrument : CARTO™ , Biosense Webster , Electrophysiology（EP）recording system , Thermocool® SmartTouch™ Catheter，Lasso/Navi-Lasso catheter , etc . NO . case : 20 Study duration : 2 month Strategy：Circumferential pulmonary vein isolation Procedure： Local anaesthesia , Sedation Catheters advance right/left femoral vein . After double transseptal puncture , 8F 8.5F SL1 Swartz sheath Steerable sheath ( e.g . Agilis , St Jude ) place left atrium ( LA ) , follow PVs ' venography Establishment anatomical model LA PVs : Respiratory gating , Point-by-Point Fast Anatomical Mapping ( FAM ) . When use Point-by-Point , CF would control 5 10g . When use FAM , model around PVs would adjust SmartTouch catheter CF 5-10g . Parameter set : Power-anterior wall 35W , posterior wall 30W ; Irrigated flow rate = 17-30ml/min；Impendence - 170Ω； Operator : Dr. Chenyang Jiang Ablation catheter could move , electrical activity amplitude decrease &gt; 80 % , impedance decrease &gt; 10Ω , ablation time 20 . Endpoint : Bi-directional block leave atrial pulmonary vein ( LA-PV ) , capture along CPVI line . The operator blind CF data , would monitor assistant . When CF high 40g , operator warn . Parameters : total procedure time , model reconstruction time , power , ablation time , impedance , CF , force-time integral ( FTI ) . Introduction PV ablation : Perform circumferential PV ablation order . 1 . When PV isolate circular linear ablation without touch-up ablation , 30min wait time + isoproterenol（ISP）/adenosine triphosphate（ATP） induction would perform detect acute reconnection . If 's reconnection , segment identify `` isolated segment '' , ablation CF , time , FTI , power segment record . 2 . When PV isolate initially , reconnected 30min+ISP/ATP observation , re-isolation would perform , segment conduction gap ( GAP ) identify `` acute reconnected segment ( ) '' . 3 . If PV isolation achieve initial circumferential ablation , additional ablation along circular lesion perform PV isolate , segment ( ) re-ablated identify `` unisolated segment ( ) '' , record parameter . 30min+ISP/ATP detection perform isolation , `` isolated segment ( ) '' `` acute reconnected segment ( ) '' identify , describe a. b . If `` acute reconnected segment ( ) '' segment ( ) `` unisolated segment ( ) '' , classify latter group . Analysis appropriate CF For segment , single variable multiple regression analysis perform three group ( `` isolate segment '' , '' acute reconnected segment `` , `` unisolated segment '' ) , define `` appropriate CF '' . The sensitivity specificity `` appropriate CF '' analyze . Phase II : Instrument : CARTO™ , Biosense Webster , EP record system , Thermocool® SmartTouch™ Catheter，Lasso/Navi-Lasso catheter , etc . NO . case : 120 Study duration : enrollment - 12 month , follow-up - 12 month , Data analysis paper preparation - 3 month . Strategy：Circumferential pulmonary vein isolation Patients randomize 1:1 ratio one two follow group : `` CF guide group '' `` usual ablation group '' . Procedure： The preparation , include anaesthesia , sedation , vascular access , transseptal puncture , describe phase I. CF guide group : After establishment anatomical model LA PVs ( phase I ) , ablation perform guidance real-time CF , ablation time , FTI , etc . CF control range `` appropriate CF '' , define phase I. Circumferential PV ablation perform orderly , `` isolate segment '' , '' acute reconnected segment `` , `` unisolated segment '' also identify described phase I. Endpoint : bi-directional block LA-PV , capture along CPVI line . Parameters record : total procedure time , model reconstruction time , power , ablation time , impedance , CF , FTI . Usual ablation group : Operator blind CF data , procedure performance describe phase I . Follow-up Warfarin new oral anticoagulant administer patient least 3months procedure . The international normalized ratio control 2.0 3.0 warfarin prescribe . After discharge , patient follow 1 , 3 , 6 , 9 , 12months post ablation . Patients ' experience , 12-lead electrocardiogram ( ECGs ) Holter monitoring ( non-required 1 , 9 month ) record evaluate recurrence appointment ( include 1 3 month visit post procedure ) visit patient experience symptom suggestive arrhythmia . The first 3 month consider blanking period . Recurrence define AF/flutter/tachycardia , last long 30 , document ECG Holter record , highly suggestive symptom , 3 month post-procedure . Primary end point : Freedom AF recurrence ECGs Holter monitor visit period 3 month 1 year procedure , independent antiarrhythmic drug ( AAD ) therapy . Secondary end point : ( 1 ) Freedom AF recurrence , dependent AAD therapy ; ( 2 ) Freedom arrhythmia-related symptom ; ( 3 ) Safety Outcomes , contain mortality ( death overall procedure-related ) , vascular access complication ( bleed , hematoma , pseudoaneurysm , arteriovenous fistula ) , periprocedural event ( stroke , transient ischemic attack , cardiac tamponade , pulmonary embolism , deep vein thrombosis , embolism , LA-esophageal fistula , Other fistula , pericardial effusion , PV stenosis , atrioventricular block , heart failure exacerbation , need pacemaker , phrenic nerve injury , acute coronary artery occlusion , valve injury ) . Follow-up terminate maximum follow-up period 12 month . Data Management Requirements investigator data entry The investigator ensure data enter medical record Case Report Forms ( CRFs ) truthfully , precisely , completely , timely legally . Information patient sign Informed Consent Form enter trial consider eligible screen closely observe record CRFs without field leave blank miss . All data CRFs check source record consistency . As source document , CRFs revise draw single line investigator 's signature date revision add . Source laboratory test report ( copy ) adhere field adhere laboratory test report medical record . Data significantly high low outside clinically acceptable range carefully verify review , necessary explanation give investigator . Requirements monitor data monitor The monitor pay regular visit site examine status signing inform consent , screen enrollment . Ensure CRFs correctly fill consistent source data . Ensure error miss data correct explain , sign date investigator . Changes treatment , concomitant medication , intercurrent condition ECG recording confirm record subject . Discontinuations loss-to-follow-ups subject indicate CRFs . Confirm adverse event ( AEs ) file . Establishment database data entry Establishment database：A study-specific database system establish per item CRF . Data entry : Data enter concurrently data manager double entry . Data review : Each data item verified discrepancy report . The source form verify item-by-item basis error correct . In case doubt data entry , data manager may fill Data Query Form return monitor . When investigator resolve write query query form sign , form send back data manager . Data Query Forms appropriately stored.Selection withdrawal subject Statistical analysis Phase I For segment , single variable multiple regression analysis perform three group ( `` isolate segment '' , '' acute reconnected segment `` , `` unisolated segment '' ) , define `` appropriate CF '' . The sensitivity specificity `` appropriate CF '' analyze . Phase II Log-rank test use inter-group comparison recurrence . Kaplan-Meier method use estimation currency curve point . When consider central effect important prognostic factor , Cox proportional risk model use estimate risk compare blank confidence interval . More data `` initially-isolated segment '' , `` initially- nonisolated segment '' , `` additionally-isolated segment '' collect , `` appropriate CF '' re-analyzed .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Age : 18 75 year Symptomatic PAF refractory least one antiarrhythmic drug Minimum two episode recurrent selfterminating AF within prior 12 month late document episode within 6 month prior ablation procedure First catheter ablation Patient able willing provide write informed consent . Persistent longstanding persistent AF &gt; 4 cardioversions prior 12 month Myocardial infarction ( MI ) , coronary artery bypass grafting ( CABG ) percutaneous coronary intervention ( PCI ) within precede 3 month Left atrial diameter &gt; 5.0 cm &lt; 3.5 cm Left ventricular ejection fraction echocardiography &lt; 40 % New York Heart Association（NYHA）class III IV History heart surgery previous ablation AF Intracardiac thrombus Females pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>Catheter Ablation</keyword>
	<keyword>contact force</keyword>
	<keyword>Chinese-specific</keyword>
</DOC>